![]() |
|
| Profile for Biomaven |
| Add PeopleMark | Ignore Member | Send Private Message | Recent Posts |
| Posts by Biomaven |
| Message | Subject | Recs | Date/Time (ET) |
| Both ubiquinol and COQ10 are found in the body, so it makes sense to me to suppl | Biotech Valuation | 05/23/2013 09:37:56 PM | |
| (I take 100mg of both ubiquinol and COQ10. Ubiquinol is the reduced form of COq1 | Biotech Valuation | 05/23/2013 02:34:20 PM | |
| >statins and exercise It's been suggested that anti-oxidants in general have | Biotech Valuation | 05/23/2013 11:22:27 AM | |
| >>The activity in MTC makes me wonder if pona will have a similar (to cabo) effe | ARIAD Pharmaceuticals | 05/23/2013 11:09:19 AM | |
| [blockquote]penned on XNPT that was very good[/blockquote] Well it might have se | Biotech Valuation | 05/22/2013 03:44:06 PM | |
| >>Anyone ever find anything of value on SeekingAlpha? Not usually in biotec | Biotech Valuation | 05/22/2013 02:31:47 PM | |
| >>Nexium worked for me better than Zegerid or other omeprazole when I had acid r | Biotech Valuation | 05/22/2013 12:33:27 PM | |
| Nexium is the biggest disgrace in our health care system. I partly blame the ins | Biotech Valuation | 05/21/2013 11:51:54 PM | |
| Ponatinib in FGFR. Perhaps the biggest wild-card for Ariad is the potential o | ARIAD Pharmaceuticals | 4 | 05/21/2013 01:34:42 PM |
| Just read a fascinating evolutionary biology article about the comb jelly. Ba | Biotech Valuation | 1 | 05/17/2013 11:29:14 PM |
| >>exceptional effectiveness Or exceptional side effects. :) Peter | Biotech Valuation | 05/17/2013 06:09:31 PM | |
| There is at least some evidence that many different mutations are already presen | ARIAD Pharmaceuticals | 05/17/2013 04:05:19 PM | |
| >> this trial was not [i]blinded[/i] To be more precise, the trial itself was | Biotech Valuation | 1 | 05/17/2013 03:23:47 PM |
| [blockquote]if a mutation is wiped out once, can it re-emerge at a later date si | ARIAD Pharmaceuticals | 05/17/2013 03:06:06 PM | |
| [url=http://www.ncbi.nlm.nih.gov/pubmed/23648372#]Clin Gastroenterol Hepatol.[ | Biotech Valuation | 2 | 05/16/2013 11:44:12 PM |
| I'd always assumed it was to reduce competition between different cicada broods. | Biotech Valuation | 05/16/2013 04:51:50 PM | |
| They pretty much had to present something at ASCO. I doubt the data will be all | Biotech Valuation | 05/16/2013 03:14:27 PM | |
| I follow SNTA, but it's very hard to handicap this data. I'd say 60:40 they have | Biotech Valuation | 05/16/2013 02:34:40 PM | |
| All the info in the pona abstracts looks positive to me. Cardiac AE's look low a | ARIAD Pharmaceuticals | 05/15/2013 11:03:53 PM | |
| >>Oh and they just announced the sale of stock and debt and the stock jumps alm | 50% Gains Investing | 05/15/2013 08:53:23 PM | |
| Must-read piece on Ranbaxy fraud: [url=http://features.blogs.fortune.cnn.com/ | Biotech Valuation | 1 | 05/15/2013 02:52:13 PM |
| I'd add that Aria's views on this (Gleevec patent) are pretty irrelevant. We are | ARIAD Pharmaceuticals | 05/15/2013 10:34:01 AM | |
| >>Gleevec is likely to win extended patent protection to 2019 on polymorph paten | ARIAD Pharmaceuticals | 05/15/2013 09:41:46 AM | |
| [blockquote]I'm curious as to how these reaction times were measured ?[/blockquo | Biotech Valuation | 05/14/2013 02:50:56 PM | |
| The correlation between IQ and simple reaction time is not great - between 0.2 a | Biotech Valuation | 2 | 05/13/2013 03:59:08 PM |
| [blockquote]PD-1 inhibitor[/blockquote] Agreed - this class of drugs is basicall | Biotech Valuation | 1 | 05/12/2013 03:35:39 PM |
| Here's some additional support for supplementing some statins with COQ10: [ | Biotech Valuation | 1 | 05/10/2013 11:53:36 PM |
| This work is in fruit flies. A very long way from assuming the same mechanism ha | Biotech Valuation | 05/10/2013 11:49:49 PM | |
| Perhaps relevant: [url=http://www.ncbi.nlm.nih.gov.ezp-prod1.hul.harvard.ed | Incyte Pharmaceuticals (INCY) | 05/09/2013 10:37:07 PM | |
| Brilliant work by Sawyer's group elucidating resistance mechanisms to Xtandi: | Biotech Valuation | 05/09/2013 10:11:03 PM | |
| High-intensity interval training: [url=http://journals.lww.com/acsm-healthfit | Biotech Valuation | 05/09/2013 06:54:36 PM | |
| >1 gram is not enough to make a dent. That might be, although they did see so | Biotech Valuation | 05/09/2013 06:54:02 PM | |
| >Fannie Mae Preferred These are up 50% since I posted about them here. I' | 50% Gains Investing | 05/09/2013 05:16:39 PM | |
| The FDA has warned that magnesium deficiency can occur in patients on proton pum | Biotech Valuation | 05/08/2013 01:22:41 PM | |
| [blockquote]I hope we can at least agree that it makes sense for folks to have t | Biotech Valuation | 05/06/2013 12:19:34 AM | |
| [blockquote]small research products company [/blockquote] That's my take too. Un | Biotech Valuation | 05/05/2013 07:56:14 PM | |
| This was a very large study - I suspect the largest there has been. With any | Biotech Valuation | 05/05/2013 05:19:40 PM | |
| [blockquote]Does this Boston related speculation also ring true ?[/blockquote] W | Biotech Valuation | 05/05/2013 04:01:37 PM | |
| That is indeed a brilliant concept. Peter | Biotech Valuation | 05/03/2013 04:14:09 PM | |
| [blockquote]Since only 3% of Israelis tested had vitamin D levels above 36 ng/mL | Biotech Valuation | 05/03/2013 12:17:27 AM | |
| Yes, of course these accounting issues are material in the [i]accounting [/i]sen | 50% Gains Investing | 05/02/2013 01:34:58 PM | |
| [blockquote] it seems strange that in a country like Israel, where there’s lots | Biotech Valuation | 05/02/2013 01:20:27 PM | |
| >>would an insider buying at these levels prior to public disclosure of the ques | 50% Gains Investing | 05/01/2013 10:31:56 PM | |
| [blockquote] I imagine the curve would look more v-shaped.[/blockquote] They don | Biotech Valuation | 05/01/2013 07:52:42 PM | |
| We've discussed this J-shaped curved for Vitamin D before: [url=http://www.si | Biotech Valuation | 05/01/2013 04:45:09 PM | |
| >>What about morbidity risk from non-coronary causes? Endpoint was a combined | Biotech Valuation | 05/01/2013 03:31:00 PM | |
| Only exclusion was "prior diagnosis of acute coronary syndrome." Peter | Biotech Valuation | 05/01/2013 02:51:33 PM | |
| Just a further clarification on the LDL risk: The 0.87 HR for the high LDL l | Biotech Valuation | 05/01/2013 12:27:49 PM | |
| [blockquote][i]a stat sig increase in coronary morbidity for people with LDL lev | Biotech Valuation | 05/01/2013 09:42:04 AM | |
| One has to be very cautious with these observational studies. There are all sort | Biotech Valuation | 04/30/2013 11:47:09 PM |
| Home | Hot | SubjectMarks | PeopleMarks | Keepers | Settings |
| Terms Of Use | Contact Us | Copyright/IP Policy | Privacy Policy | About Us | FAQ |